The commercialization of Caronic anhydride in ABA has succeeded
The commercialization of Caronic anhydride (CAS no.: 67911-21-1), the strategic pharmaceutical intermediate of ABA, has succeeded. The current production capability can reach 20mt per month.
We ABA fully own the intellectual property of the production technology of Caronic anhydride (patent no. ZL.201410364816.2)
Last one：CPhI：ACL at CPhI Worldwide Eur ...
Next article：ABA rewarded with “Partnership ...